Compare American Express Co (AXP) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs ResMed Inc. — how do they compare? American Express Co trades at $355.22 (market cap $242.27B), while ResMed Inc. trades at $193 (market cap $28.00B). The key difference: American Express Co is far larger — about 8.7× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.24%). Which is the better fit depends on your goals.
| AXP | RMD | |
|---|---|---|
Market Cap | $242.27B | $28.00B |
Sector | Financials | Health |
52-Week High | $384.82 | $293.73 |
52-Week Low | $292.27 | $182.82 |
Dividend Yield | 1.07% | 1.24% |
Enterprise Value | — | $27.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $354.43, up 1.1% today, with a bullish technical signal from moving averages and support at $352. The company reported strong Q1 2026 earnings of $4.28 per share, beating estimates, with revenue reaching $72.23 billion in 2025. Recent news highlights AI investments and a new headquarters, while analyst consensus is a $373.62 price target with 40% buy ratings.
Outlook remains positive driven by revenue growth and premium cardholder expansion, but risks include economic sensitivity and rising debt levels. The stock offers potential upside to consensus targets, supported by institutional confidence and operational momentum, though investors should monitor spending trends and interest rate impacts.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
